Medplus Health Serv.

Medplus Health Services' promoter Lone Furrow Investments created an additional pledge of 29 lakh equity shares on July 24, 2026, in favour of debenture trustee Catalyst Trusteeship Limited, to restore the security cover ratio under an existing share pledge agreement. The new pledge raised Lone Furrow’s total encumbered holding to 54 lakh shares and lifted the overall promoter encumbrance to 68.62 per cent of promoter shareholding. Promoter pledging has been a recurring feature at Medplus; an earlier spike to 69.4 per cent in December 2025 was followed by a partial release that brought the ratio back to 60.7 per cent. Medplus operates the country’s second-largest pharmacy retail chain, with revenue of Rs 68,924 million in FY26 and a net cash balance sheet.

Powered by Tijori

Lone Furrow Investments Private Limited, a promoter of Medplus Health Services, pledged an additional 29,00,000 equity shares on 24 July 2026 to restore the security cover ratio on an existing ₹550 crore non-convertible debenture facility. The top-up lifted Lone Furrow's total encumbered shares to 54,00,000, or 4.49 per cent of the company's equity, while combined promoter encumbrance stood at 68.62 per cent of promoter shareholding. Promoter encumbrance had briefly touched 69.4 per cent in December 2025 before declining to 60.7 per cent by end-December following a partial release of pledged shares. Medplus Health Services reported revenue of ₹18,796 million for the June 2026 quarter, a 22 per cent year-on-year increase, while operating margins contracted to 3.5 per cent. The debenture facility, originally issued by Dureleg Manufacturing and now assumed by Lone Furrow through a scheme of amalgamation, carries a security cover ratio of 2.10 times.

Powered by Tijori

MedPlus Health Services suspended two capital expenditure projects that its board had approved just two days earlier, citing a reassessment of business conditions and the market outlook. The shelved plans included a food park being set up by a material subsidiary, Optical Health Solutions, and a concierge health and wellness facility in Hyderabad. The board took the decision on 23 July after a review of the company's structure, though it said the move would not affect existing operations or business performance.

Powered by Tijori

July 23 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES - KEEPS FOOD PARK AND CONCIERGE HEALTH FACILITY CAPEX IN ABEYANCE

• MEDPLUS HEALTH SERVICES - KEEPS CAPEX PLANS APPROVED ON JULY 21 IN ABEYANCE

Source text: ID:nBSE1XyJLY

Further company coverage: MEDP.NS

(([email protected];))

** India's Medplus Health Services MEDP.NS slumps 15.4% to nearly 18-month low of 676 rupees

** Set for biggest daily pct drop since listing in December 2021

** Pharmacy retail-chain operator reports 22% plunge in first-quarter net profit, hurt by rising competition and increasing costs due to an aggressive store expansion strategy

** Nomura says gross profit growth at 14% year-on-year was slowest in four years, with gross margin down 163 basis points

** Attributes weak quarter to lower contribution from pharma private label and higher overhead expenses

** More than 560,000 shares change hands, ~3.6x of 30-day average daily volume

** Stock rated "buy" on average by 7 brokerage firms, median PT at 1,150 rupees, per data compiled by LSEG

** YTD, MEDP down 16.3%

(Reporting by Vivek Kumar M)

(([email protected];))

July 21 (Reuters) - Indian Pharmacy retail-chain operator MedPlus Health Services MEDP.NS on Tuesday reported an about 22% plunge in first-quarter net profit, hurt by rising competition and increasing costs due to an aggressive store expansion strategy.

• The company reported a consolidated net profit of 331.8 million rupees ($3.45 million) for the three months ended June 30, down from 423.6 million rupees a year earlier

• Costs associated with expansion for India's second-largest pharmacy retailer in terms of number of stores operated, crimped margins

• Analysts had noted that the company's store expansion and rising adoption of diabetes and obesity treatments are expected to drive long-term growth in India's organised pharmacy retail

• MedPlus reported a 21.8% increase in quarterly revenue to 18.8 billion rupees, helped by a 22% growth in retail sales

• Its Optival Health Solutions unit approved a 400 million rupees capex for a food Park with a cold-press oil extraction unit. It also plans a 1.15 billion investment for a subscription-based concierge health and wellness services facility

• MedPlus, which competes with unlisted peers such as Tata 1mg, Apollo Pharmacy and Reliance Retail's Netmeds, has plans to open 800 stores this financial year.

($1 = 96.2350 Indian rupees)

(Reporting by Saikeerthi in Bengaluru and Urvi Dugar; Editing by Joyjeet Das)

(([email protected]; (+91) 8296756080))

July 1 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES - OPTIVAL HEALTH SOLUTIONS RECEIVES SUSPENSION ORDER FOR DRUG LICENSE OF STORE IN KARNATAKA

Source text: ID:nBSE7sPV0m

Further company coverage: MEDP.NS

(([email protected];))

June 26 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES - UNIT OPTIVAL HEALTH SOLUTIONS RECEIVES THREE DRUG LICENSE SUSPENSION ORDERS IN KARNATAKA AND ANDHRA PRADESH

Source text: ID:nNSE5v2zb3

Further company coverage: MEDP.NS

(([email protected];))

June 24 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES - OPTIVAL HEALTH SOLUTIONS RECEIVES TWO DRUG LICENSE SUSPENSION ORDERS IN ANDHRA PRADESH

Source text: ID:nBSE8lhGXk

Further company coverage: MEDP.NS

(([email protected];))

** Shares of India's MedPlus Health Services MEDP.NS jump as much as 12.2% to 1,022.20 rupees; last up 7.4%

** Pharmacy chain's Q4 net profit rose 24.6% y/y to 639.8 million rupees ($6.65 million)

** Revenue from ops rose 23.5% y/y, driven by store expansion and strong same-store growth

** Co adds 218 net stores in the quarter, compared with 100 a year earlier

** Consol operating EBITDA margin increased to 5.8% from 5.3% a year earlier

** Trading vols at 9.7x the 30-day average

** MEDP rated "strong buy" on average by seven analysts, median PT: 1,110 rupees - LSEG data

** YTD, stock up ~22.2%

($1 = 96.2200 Indian rupees)

(Reporting by Bipasha Dey in Bengaluru)

(([email protected];))

April 28 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES LTD - RECEIVES TWO STAY ORDERS AGAINST SUSPENSION FROM AUTHORITIES IN PUNE, MAHARASHTRA

Source text: ID:nNSE4ncYj7

Further company coverage: MEDP.NS

(([email protected];))

April 20 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES LTD - UNIT RECEIVES TWO DRUG LICENSE SUSPENSION ORDERS FOR STORES

Source text: ID:nBSE8yGHmT

Further company coverage: MEDP.NS

(([email protected];))

** Shares of Medplus Health Services MEDP.NS fall 4.8% to 874 rupees

** Stock marks steepest intraday pct loss since January 14

** Nomura maintains "buy" rating; cuts price target to 1,030 rupees from 1,050 rupees

** New PT implies 12.1% upside to last close, compared to previous PT's 14.2% upside

** Says Q1 results missed estimates due to higher employee expenses

** Brokerage lowers fiscal 2026 and 2027 operating EBITDA estimates by ~15%/22%, factoring in slower revenue growth and elevated overheads

** MEDP rated "strong buy" by six analysts on average; median target price is 1,087.5 rupees – data compiled by LSEG

** Stock up 5.2% YTD

(Reporting by Rudra Pratap Singh in Bengaluru)

(([email protected]))

Feb 19 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• STAY ORDER GRANTED AGAINST DEMAND OF 18.9 MILLION RUPEES

Source text: ID:nBSE2P9g0R

Further company coverage: MEDP.NS

(([email protected];;))

Jan 31 (Reuters) - India's MedPlus Health Services MEDP.NS reported a surge in third-quarter profit on Friday, driven by store expansions and strong demand for over-the-counter medicines.

The company's consolidated net profit more than tripled to 458.8 million rupees ($5.3 million) in the quarter ended Dec. 31.

MedPlus continued to benefit from strong sales of products under its private label brands in both the pharmaceuticals and consumer wellness categories, which analysts say contribute more to its margins.

The company's revenue from operations rose 8.3% to 15.61 billion rupees, led by an 8% jump in its retail business.

While MedPlus does not break up its revenue from OTC medicines and devices, etc, they are all part of its retail business, which makes up nearly all of the company's revenue.

The company currently has more than 4,000 outlets across the country, trailing only Apollo Pharmacy's count of nearly 6,000 stores. Last year, MedPlus said it plans to open 600 stores to increase its presence in smaller cities.

MedPlus competes with Reliance Industries' RELI.NS Netmeds and Apollo Pharmacy, both of which are unlisted, among other retail pharmacies in the Indian OTC drug retail market.

($1 = 86.5830 Indian rupees)

(Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza)

(([email protected]; 8800437922;))

Jan 7 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• OPTIVAL HEALTH SOLUTIONS RECEIVES DRUG LICENSE SUSPENSION ORDER

Source text: ID:nBSE2nPfJT

Further company coverage: MEDP.NS

(([email protected];;))

** Shares of MedPlus Health Services MEDP.NS fall as much as 4.3% to 811 rupees before recovering slightly; last down 3.8%

** Co's unit Optival Health Solutions gets suspension order of drug license for stores in Karnataka and Maharashtra

** Stock on track for second-sharpest intraday fall in 2024

** Avg rating of six analysts is a "strong buy" and median PT is 915 rupees, ~12% higher than current price - LSEG data

** Stock trims YTD gains to around 9%

(Reporting by Anuran Sadhu in Bengaluru)

(([email protected]; +91 8697274436;))

Dec 19 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES LTD - OPTIVAL HEALTH SOLUTIONS RECEIVES DRUG LICENSE SUSPENSION ORDER

Source text: ID:nBSE9dL6xb

Further company coverage: MEDP.NS

(([email protected];))

Nov 28 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES - UNIT GOT ONE SUSPENSION ORDER OF DRUG LICENSE FOR FOUR DAYS AT ONE STORE

• MEDPLUS HEALTH SERVICES - POTENTIAL REVENUE LOSS OF 250,000 RUPEES FROM ORDER

Source text: ID:nNSE15b7k9

Further company coverage: MEDP.NS

(([email protected];))

Nov 18 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• PI OPPORTUNITIES FUND-I SOLD 6.9 MILLION SHARES OF MEDPLUS HEALTH SERVICES AT 700 RUPEESPER SHARE VIA BULK DEAL - EXCHANGE DATA

• SBI MUTUAL FUND SOLD 1 MILLION SHARES OF MEDPLUS HEALTH SERVICES AT 700 RUPEESPER SHARE VIA BULK DEAL - EXCHANGE DATA

Source text: [ID:]

Further company coverage: MEDP.NS

(([email protected];;))

** Shares of MedPlus Health Services MEDP.NS rise as much as 7.4% to 724.95 rupees

** MEDP on Tuesday reported its Q2 consol net profit to more than doubled to 387.4 mln rupees ($4.6 mln); rev from ops rose ~12% Y/Y

** Co's retail business, which accounts for nearly all of its revenue, rose 11.3% Y/Y

** More than 1.5 mln shares change hands, 6.5x of 30-day avg

** Avg rating of six analysts equivalent to "strong buy", median PT is 840 rupees - LSEG data

** Stock down 6.5% YTD

($1 = 84.4000 Indian rupees)

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

Nov 12 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• SEPT-QUARTER CONSOL NET PROFIT 387.4 MILLION RUPEES

• SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 15.76 BILLION RUPEES

Source text: ID:nBSE5wv4NY

Further company coverage: MEDP.NS

(([email protected];))

Oct 31 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• UNIT RECEIVED FIVE SUSPENSION ORDERS OF DRUG LICENSE

Source text: ID:nBSEc5fS70

Further company coverage: MEDP.NS

(([email protected];;))

Aug 20 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES LTD - UNIT RECEIVED TWO SUSPENSION ORDERS OF DRUG LICENSE

Source text for Eikon: ID:nNSE5Vk96x

Further company coverage: MEDP.NS

(([email protected];))

Aug 2 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES Q1 CONSOL NET PROFIT 143.6 MILLION RUPEES

• MEDPLUS HEALTH SERVICES Q1 CONSOL REVENUE FROM OPERATIONS 14.89 BILLION RUPEESS

Source text for Eikon: ID:nBSE1XHvFg

Further company coverage: MEDP.NS

(([email protected];))

July 24 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• MEDPLUS HEALTH SERVICES - UNIT GOT 3 DAYS SUSPENSION ORDER FOR TRICHY STORE

Further company coverage: MEDP.NS

(([email protected];))

July 5 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• RECEIVED STAY ORDER AGAINST EARLIER SUSPENSION ORDER

Further company coverage: MEDP.NS

(([email protected];))

June 28 (Reuters) - MedPlus Health Services Ltd MEDP.NS:

• RECEIVED TWO DAYS SUSPENSION ORDER OF DRUG LICENSE FOR A STORE SITUATED AT HYDERABAD

• POTENTIAL REVENUE LOSS OF 0.15 MILLION RUPEES DUE TO THE SUSPENSION ORDER

Further company coverage: MEDP.NS

(([email protected];))

** Shares of MedPlus Health Services MEDP.NS down 2.5% to 712.8 rupees

** Stock among few losers amid jump in broader markets .BO

** The retail pharmacy co says its unit got four days suspension order for store in Warangal, Telangana

** Stock on track to log biggest one-day drop since early-Feb

** Analysts' avg rating on stock is equivalent of "Buy", their median PT is 855 rupees, per LSEG data

** Including session's losses, stock down ~5% YTD

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

BENGALURU, May 28 (Reuters) - India's MedPlus Health Services MEDP.NS reported a rise in fourth-quarter profit on Tuesday, driven by retail sales.

MedPlus, which sells online and in retail stores, said consolidated net profit climbed 25.6% year-on-year to 333.96 million rupees ($4 million) for the three months to March 31.

Analysts expect the retail pharmaceutical sector to see strong growth in the near term and an increasing market share for organised players such as MedPlus. Store network expansion and an uptick in branded prescription medicines are expected to boost sales further.

New drug launches and improving medical infrastructure have also improved access to these medicines, driving sales of retail pharmacies.

MedPlus said revenue from operations rose nearly 19% to 14.90 billion rupees.

Revenue from its retail business, which constituted 98% of its net sales, jumped more than 18%, while revenue from its diagnostics business surged 94.6%.

Expenses rose 17.6%, mainly due to higher procurement costs of medicines it sells.

MedPlus competes with Reliance-owned RELI.NS Netmeds and Apollo Pharmacies among other retail pharmacies in the Indian OTC drugs market.

Shares of MedPlus closed 1.6% lower ahead of the result.

($1 = 83.1700 Indian rupees)

(Reporting by Kashish Tandon and Varun Hebbalalu in Bengaluru; Editing by Sohini Goswami)

(([email protected];))